Addendum
Sacituzumab govitecan (breast cancer) – Addendum to Project A23-86
Report documents
-
Addendum
Sacituzumab govitecan (breast cancer) – Addendum to Project A23-86
Dossier assessment
Indication:
Adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least 2 additional systemic therapies in the advanced setting
Result of dossier assessment:
After addendum now: proof of considerable added benefit
Additional information
Federal Joint Committee (G-BA)
2024-02-15 A G-BA decision was published.
Project details
- Project no.
- A24-07
- Commission
- Commission awarded on 09.01.2024 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://dx.doi.org/10.60584/A24-07_en
Connected Projects
-
Dossier assessment
Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed